Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 428,400 shares, a growth of 152.1% from the September 15th total of 169,900 shares. Based on an average daily volume of 217,700 shares, the days-to-cover ratio is currently 2.0 days. Approximately 10.6% of the company’s stock are short sold. Approximately 10.6% of the company’s stock are short sold. Based on an average daily volume of 217,700 shares, the days-to-cover ratio is currently 2.0 days.

Verrica Pharmaceuticals Trading Down 1.9%

Shares of Verrica Pharmaceuticals stock opened at $4.15 on Monday. The stock has a fifty day simple moving average of $4.99 and a 200 day simple moving average of $5.61. Verrica Pharmaceuticals has a 12-month low of $3.82 and a 12-month high of $17.38. The company has a market capitalization of $39.22 million, a P/E ratio of -0.50 and a beta of 1.71.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.72. The company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $4.37 million. On average, analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several large investors have recently made changes to their positions in VRCA. Sovran Advisors LLC increased its position in shares of Verrica Pharmaceuticals by 91.3% during the 2nd quarter. Sovran Advisors LLC now owns 750,391 shares of the company’s stock valued at $398,000 after purchasing an additional 358,228 shares during the last quarter. Armistice Capital LLC increased its position in shares of Verrica Pharmaceuticals by 3.7% during the 2nd quarter. Armistice Capital LLC now owns 8,881,344 shares of the company’s stock valued at $4,708,000 after purchasing an additional 313,944 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at $99,000. Marshall Wace LLP purchased a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at $66,000. Finally, Bank of America Corp DE increased its position in shares of Verrica Pharmaceuticals by 347.5% during the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after purchasing an additional 111,678 shares during the last quarter. 42.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $60.00.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.